Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.39 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19788055 | 1.00 | FOLH1 (0.42) | FOLH1PRMT1EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL19360008 | 0.83 | PRMT1 (0.49) | FOLH1PRMT1EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL15275337 | 0.81 | EPHX1 (0.49) | FOLH1PRMT1EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL2742770 | 0.81 | FOLH1 (0.48) | FOLH1PRMT1EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL12304382 | 0.81 | FOLH1 (0.63) | FOLH1EPHX2RIMKLANAALAD2 | |
| SCHEMBL15828219 | 0.80 | GABRP (0.42) | FOLH1PRMT1EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL12118207 | 0.79 | PRMT1 (0.45) | FOLH1PRMT1EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL24253219 | 0.78 | FOLH1 (0.42) | FOLH1ANPEPENPEPRIMKLANAALAD2 | |
| SCHEMBL15762839 | 0.76 | PRMT1 (0.44) | FOLH1PRMT1EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL12553859 | 0.73 | MAPK1 (0.56) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125854-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME | PFIZER INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9895378-B2 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same | PFIZER INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9877923-B2 | Process for preparing therapeutic nanoparticles | PFIZER INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170266187-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | PFIZER INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170209374-A1 | METHODS OF CONTROLLING THE MORPHOLOGY OF POLYMERIC NANOPARTICLES | PFIZER (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170151181-A1 | METHODS OF TREATING CANCERS WITH THERAPEUTIC NANOPARTICLES | PFIZER INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170119672-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods Of Making And Using Same | PFIZER INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-9579386-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | PFIZER INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20170049709-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170042855-A1 | NANOPARTICLES COMPRISING DOCETAXEL FOR TREATING CANCERS HAVING A K-RAS MUTATION | BIND THERAPEUTICS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20130115192-A1 | Methods for the Preparation of Targeting Agent Functionalized Diblock Copolymers for Use in Fabrication of Therapeutic Targeted Nanoparticles | BIND BIOSCIENCES, INC (US) | 2013-05-09 | — | — | US | disclosed |
| US-8318208-B1 | Drug loaded polymeric nanoparticles and methods of making and using same | BIND BIOSCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120288541-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120276162-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2012-11-01 | — | — | US | disclosed |
| US-8293276-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | BIND BIOSCIENCES, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8273363-B2 | Cancer cell targeting using nanoparticles | BIND BIOSCIENCES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8236330-B2 | Cancer cell targeting using nanoparticles | BIND BIOSCIENCES, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120004293-A1 | Cancer Cell Targeting Using Nanoparticles | PFIZER INC. | 2012-01-05 | — | — | US | disclosed |
| US-20110274759-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2011-11-10 | — | — | US | disclosed |
| US-20110224288-A1 | Cancer Cell Targeting Using Nanoparticles | PFIZER INC. | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120276162-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | CD47, LPXN, CD44 | FOLH1 173/4885PRMT1 3860/4885EPHX2 1007/4885 |
| US-20110274759-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | LDHA, LDHB, LPXN | FOLH1 177/4885PRMT1 3790/4885EPHX2 1542/4885 |
| US-20170119672-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods Of Making And Using Same | CD44, NCL, TP53 | FOLH1 40/4885PRMT1 1684/4885EPHX2 3646/4885 |
| US-20110224288-A1 | Cancer Cell Targeting Using Nanoparticles | CD47, EPCAM, CD44 | FOLH1 279/4885PRMT1 2310/4885EPHX2 1613/4885 |
| US-20130115192-A1 | Methods for the Preparation of Targeting Agent Functionalized Diblock Copolymers for Use in Fabrication of Therapeutic Targeted Nanoparticles | GNE, PAM, EPHA2 | FOLH1 727/4885PRMT1 3811/4885EPHX2 16/4885 |
| US-20180125854-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME | TP53, HNRNPH3, VHL | FOLH1 336/4885PRMT1 1482/4885EPHX2 4038/4885 |
| US-20120288541-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | CD47, LPXN, CD44 | FOLH1 173/4885PRMT1 3860/4885EPHX2 1007/4885 |
| US-20170209374-A1 | METHODS OF CONTROLLING THE MORPHOLOGY OF POLYMERIC NANOPARTICLES | CLTB, NCL, CLTA | FOLH1 976/4885PRMT1 4302/4885EPHX2 2715/4885 |
| US-20170266187-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | MTHFD1, TYMP, FPGS | FOLH1 51/4885PRMT1 1374/4885EPHX2 1354/4885 |
| US-20120004293-A1 | Cancer Cell Targeting Using Nanoparticles | CD47, EPCAM, CD44 | FOLH1 279/4885PRMT1 2310/4885EPHX2 1613/4885 |
| US-20170151181-A1 | METHODS OF TREATING CANCERS WITH THERAPEUTIC NANOPARTICLES | KRAS, TP53, NRAS | FOLH1 336/4885PRMT1 2506/4885EPHX2 3791/4885 |
| US-20170042855-A1 | NANOPARTICLES COMPRISING DOCETAXEL FOR TREATING CANCERS HAVING A K-RAS MUTATION | KRAS, NRAS, HRAS | FOLH1 1995/4885PRMT1 3362/4885EPHX2 3748/4885 |
| US-20170049709-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | CTSA, GAA, EEA1 | FOLH1 135/4885PRMT1 3820/4885EPHX2 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.